BOX SER

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. DEX-0269

Total Pages in this Submission

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application Washington, D.C. 20231

	washington, b.c. 2020	
Transmitted here	ewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application	n for an
invention entitled		
COMPOSITIO	ONS AND METHODS RELATING TO BREAST SPECIFIC GENES AND PROTEINS	. PTO
		90.8 90.18
and invented by:		-
Salceda et al.		110
If a CONTINUA	TION APPLICATION, check appropriate box and supply the requisite information:	
☐ Continuat	ion Divisional Continuation-in-part (CIP) of prior application No.:	
Which is a: ☐ Continuat	ion Divisional Continuation-in-part (CIP) of prior application No.:	
Which is a:		
□ Continuat #	ion Divisional Continuation-in-part (CIP) of prior application No.:	
Enclosed are:		
*·—··	Application Elements	
1. 🗵 Filir	ng fee as calculated and transmitted as described below	
2. 🗵 Spe	ecification having pages and including the following:	
a. 🗵	Descriptive Title of the Invention	
b. 🗷	Cross References to Related Applications (if applicable)	
c. 🗆	Statement Regarding Federally-sponsored Research/Development (if applicable)	
d. 🔲	Reference to Microfiche Appendix (if applicable)	
e. 🛚	Background of the Invention	
f. 🗵	Brief Summary of the Invention	
g. 🛘	Brief Description of the Drawings (if drawings filed)	
h. 🛚	Detailed Description	
i. 🗵	Claim(s) as Classified Below	
j. 🗷	Abstract of the Disclosure	

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. DEX-0269

Total Pages in this Submission

3.		Drawing(s) (when necessary as prescribed by 35 USC 113)						
	a.	☐ Formal Number of Sheets						
	b.	☐ Informal Number of Sheets						
4.	X	Oath or Declaration						
	a.	☐ Newly executed (original or copy)						
	b.	☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)						
	C.	☑ With Power of Attorney ☐ Without Power of Attorney						
	d.	DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).						
5.		Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.						
6.		Computer Program in Microfiche (Appendix)						
7.	X	Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)						
	a.	☑ Paper Copy						
	b.	☑ Computer Readable Copy (identical to computer copy)						
	C.	Statement Verifying Identical Paper and Computer Readable Copy						
		Accompanying Application Parts						
8.		Assignment Papers (cover sheet & document(s))						
9.		37 CFR 3.73(B) Statement (when there is an assignee)						
10.		English Translation Document (if applicable)						
11.		Information Disclosure Statement/PTO-1449						
12.		Preliminary Amendment						
13.	X	Acknowledgment postcard						
14.	X	Certificate of Mailing						
		☐ First Class ☒ Express Mail (Specify Label No.): EV051546943US						

Application Elements (Continued)

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. DEX-0269

Total Pages in this Submission

	Accompanying Application Parts (Continued)								
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)							
16.		Additional Enclosures (please identify below):							
		Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)							
17.		Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.							
		Warning							
		An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.							

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. DEX-0269

Total Pages in this Submission

Fee Calculation and Transmittal

		CLAIMS A	S FILED			
For	#Filed	#Allowed	#Extra		Rate	Fee
Total Claims	19	- 20 =	0	x	\$18.00	\$0.00
Indep. Claims	2	- 3 =	0	x	\$84.00	\$0.00
Multiple Dependent Claims (check if applicable)						\$280.00
ngi ngi					BASIC FEE	\$740.00
OTHER FEE (specify	purpose)					\$0.00
					TOTAL FILING FEE	\$1,020.00
☑ Credit any☑ Charge an☐ Charge the	v. A duplicate of amount of overpayment. y additional filing issue fee set in 37 C.F.R. 1.3	copy of this sheet as ng fees required u in 37 C.F.R. 1.18	is enclosed is filing fee. under 37 C.F. at the mailing K. L. 60 M. T.	F.R. 1.16 Ing of the Athleen	and 1.17. Notice of Allowance, Signature A. Tyrrell, Registration No. Tyrrell P.C. ain Street N.J. 08053	38,350

CERTIFICATE OF EXPRESS MAILING

"Express Mail" Label No. EV051546943US Date of Deposit: November 20, 2001

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R 1.10 on the date indicated above and is addressed to the "BOX SEQUENCE", Assistant Commissioner for Patents, Washington, D.C. 20231.

- 1) Patent Application Transmittal Letter (2 copies);
- 2) Application consisting of 143 pages of Specification, including three (3) pages of Claims and one (1) page of Abstract;
- 3) Return Postcard;
- 4) Unexecuted Declaration and Power of Attorney;
- 5) Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§1.821-1.825;
- 6) Sequence listing;
- 7) Diskette containing computer readable copy of Sequence Listing;
- 8) Check in the amount of \$1,020.00 for filing fee.

Marulles A. Tyrson Tyrkell

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.:

DEX-0269

Applicant:

diaDexus, Inc.

Inventors:

Salceda et al.

Serial No.:

Not yet assigned

Filing Date:

November 20, 2001

Examiner:

Not yet assigned

Group Art Unit:

Not yet assigned

Title:

Compositions and Methods Relating to Breast Specific Genes and Proteins

Receipt date granted

Receipt 18 11 (2010).

Down OPLA-

I, Kathleen A. Tyrrell, Registration No. 38,350, certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

On this date: November 23, 2001

9 WAMULL N. MMM

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Statement to Support Attempted Express Mailing

On November 20, 2001, I, Kathleen A. Tyrrell deposited U.S. Utility Patent Application, Attorney Docket Number DEX-0269 with the United States Post Office in Marlton, NJ with Express Mail Label EV051546943US. The Express Mail package was returned to sender on November 21, 2001.

I hereby declare that the statements made herein of my own knowledge are true and that all statements made on information and

Attorney Docket No.: DEX-0269

Inventors: Salceda et al.
Serial No.: Not yet assigned
Filing Date: November 20, 2001

Page 2

belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application and any patent issuing thereon, or any patent to which this verified statement is directed.

Kathleen A. Tyrfell

Licata & Tyrrel P.C. 66 East Main Street Marlton, NJ 08053 Date

11-23-2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.:

DEX-0269

Inventors:

Salceda et al.

Serial No.:

Not yet assigned

Filing Date:

Herewith

Examiner:

Not yet assigned

Group Art Unit:

Not yet assigned

Title:

Compositions and Methods Relating to Breast Specific Genes and Proteins

"Express Mail" Label No. **EV051546943US** Date of Deposit - **November 20, 2001**

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for

Patents, Washington, D.C. 20231.

By Market Kathleen A. Tyrrell, Registration No. 38,350

BOX SEQUENCE

Assistant Commissioner for Patents Washington, DC 20231

Sir:

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

- (XX) I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
- () I hereby state that the submission filed in accordance with 37 CFR §1.821(q) does not include new matter.

- () I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
- I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing were made to conform with the current Sequence Listing rules. I hereby state that the substitute sheet(s) of the Sequence Listing does not include new matter.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.
-) I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), contains identical data to that originally filed.

Respectfully submitted,

Mathleen A. Tyrrell

Registration No. 3/8,350

Date: November 20, 2001

Licata & Tyrrell P.C. 66 E. Main Street Marlton, New Jersey 08053

(856) 810-1515